Prow, Natalie A.
Liu, Liang
McCarthy, Mary K.
Walters, Kevin
Kalkeri, Raj
Geiger, Jillian
Koide, Fusataka
Cooper, Tamara H.
Eldi, Preethi
Nakayama, Eri http://orcid.org/0000-0002-0826-3513
Diener, Kerrilyn R.
Howley, Paul M.
Hayball, John D.
Morrison, Thomas E.
Suhrbier, Andreas
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council
Advance Queensland Research
Australian Department of Industry Science Industry Endowment Fund
U.S. Department of Health & Human Services | U.S. Public Health Service
National Institute of Allergy and Infectious Diseases
Australian department
Australian Research Council
Daiichi Sankyo Foundation of Life Science
Article History
Received: 16 December 2019
Accepted: 24 April 2020
First Online: 2 June 2020
Competing interests
: A.S., N.A.P., P.E., L.L., T.H.C. and J.D.H. own Sementis shares. J.D.H.’s research group conducts collaborative research with Sementis financially supported, whole or in part, by Sementis. A.S. was an unpaid Scientific Advisory Board member of Sementis (2011–2019) and was an occasional paid consultant for Sementis. P.M.H. was the CEO/CSO of Sementis. L.L., T.H.C., K.R.D., P.E. and N.A.P. have had, and/or currently have, salary and/or project support from funds provided, whole or in part, by Sementis. The NHP study was undertaken by Southern Research and was contracted and overseen by the NIAID (NIH, USA) and constitutes an independent assessment of the SCV vaccine vector technology. K.W., R.K., J.G. and F.K. are employees of Southern Research. VACV antibody analyses on the stored serum samples were undertaken at Southern Research under a separate R&D contract paid for by Sementis. CHIKV serology was undertaken at the University of Colorado School of Medicine and was conducted independently of Sementis using serum samples provided by Southern Research. Sementis had no influence on the analysis and interpretation of the data.